Founded in 1988 by physician-scientists Leonard S. Schleifer and George D. Yancopoulos, Regeneron Pharmaceuticals, Inc. is a leading biotechnology company headquartered in Tarrytown, New York, and is recognized for its science-driven approach to discovering, developing, and commercializing life-transforming medicines for serious diseases. Built around proprietary technologies including VelociSuite® and the Regeneron Genetics Center®, the company has established a broad and differentiated platform spanning eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron’s portfolio includes 13 approved medicines in the United States and other countries, and as of December 31, 2025, the company employed 15,410 full-time people worldwide. In 2025, Regeneron reported total revenues of USD14.3 billion, reflecting the scale and strength of one of the biotechnology sector’s most successful innovation platforms.
Updated 2026-03-19